Whats more, they replicated the same analyses in a separate cohort of patients with type 2 diabetes mellitus by comparing semaglutide with non-GLP1R agonist anti-diabetes medications
Emerging research and patient reports have identified more severe risks, including gastroparesis (paralysis of the stomach)
Many post-op patients use medications to help with weight regain, appetite control, or metabolic issues
So, the point here being that tirzepatide is better for fat loss, but at higher doses does yield more side effects
In June, Zealand released positive data from an early trial showing that a high dose of the drug helped people lose nearly 9 percent of their body weight on average at 16 weeks
Ironically, multiple treatment guidelines and algorithms periodically released to improve guidance may generate confusion into clinicians [20]